Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | CALCA | P06881 | 9/20 | 0.35 |
| ▸ | HPGDS | O60760 | 1/20 | 0.35 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.34 |
| ▸ | CD38 | P28907 | 2/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20042333 | 1.00 | OGA (0.37) | OGACNR2CALCAHPGDSCSNK1E | |
| SCHEMBL20002012 | 1.00 | OGA (0.37) | OGACNR2CALCAHPGDSCSNK1E | |
| SCHEMBL20002350 | 0.97 | CNR2 (0.40) | OGACNR2CALCACD38 | |
| SCHEMBL20002675 | 0.96 | CD38 (0.36) | OGACALCACD38ROCK2CYP3A4 | |
| SCHEMBL20002241 | 0.92 | CD38 (0.38) | CNR2CALCACD38ROCK2CYP3A4 | |
| SCHEMBL20042318 | 0.92 | CD38 (0.38) | CNR2CALCACD38ROCK2CYP3A4 | |
| SCHEMBL20001797 | 0.91 | LMNA (0.39) | CNR2CALCACD38CYP3A4 | |
| SCHEMBL20002546 | 0.91 | LMNA (0.41) | CNR2CALCACYP3A4 | |
| SCHEMBL20001854 | 0.91 | LMNA (0.39) | CNR2CALCACD38CYP3A4 | |
| SCHEMBL20002611 | 0.89 | CD38 (0.36) | CNR2CALCACD38ROCK2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180099939-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2018-04-12 | — | — | US | disclosed |
| US-20180099939-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2018-04-12 | — | — | US | disclosed |
| WO-2018057973-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099939-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION AND INDICATIONS THEREFOR | IDO1, TDO2, IDO2 | OGA 1381/4885CNR2 324/4885CALCA 3586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.